Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Charles River Laboratories International (CRL) stocks in Canada

Learn how to easily invest in Charles River Laboratories International stocks.

Charles River Laboratories International is a diagnostics & research business based in the US. Charles River Laboratories International stocks (CRL.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $379.2 – a decrease of 5.45% over the previous week. Charles River Laboratories International employs 18,400 staff and has a trailing 12-month revenue of around $3.4 billion.

How to buy shares in Charles River Laboratories International

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CRL – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy Charles River Laboratories International stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted Charles River Laboratories International's stock price?

Since the stock market crash in March caused by coronavirus, Charles River Laboratories International's stock price has had significant positive movement.

Its last market close was $340.23, which is 48.96% up on its pre-crash value of $173.64 and 255.96% up on the lowest point reached during the March crash when the stocks fell as low as $95.58.

If you had bought $1,000 worth of Charles River Laboratories International stocks at the start of February 2020, those stocks would have been worth $647.22 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $2,191.08.

Charles River Laboratories International stock price (NYSE:CRL)

Use our graph to track the performance of CRL stocks over time.

Charles River Laboratories International shares at a glance

Information last updated 2022-01-18.
Latest market close$340.23
52-week range$249.48 - $460.21
50-day moving average $366.73
200-day moving average $378.27
Wall St. target price$443.73
PE ratio 46.534
Dividend yield N/A (0%)
Earnings per share (TTM) $7.72

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

Charles River Laboratories International price performance over time

Historical closes compared with the close of $340.23 from 2022-01-18

1 week (2022-01-12) -5.45%
1 month (2021-12-17) -6.26%
3 months (2021-10-19) -17.52%
6 months (2021-07-19) -10.06%
1 year (2021-01-19) 21.99%
2 years (2020-01-17) 112.94%
3 years (2019-01-18) 185.40%
5 years (2017-01-19) 324.92%

Is Charles River Laboratories International under- or over-valued?

Valuing Charles River Laboratories International stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Charles River Laboratories International's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Charles River Laboratories International's P/E ratio

Charles River Laboratories International's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 47x. In other words, Charles River Laboratories International shares trade at around 47x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Charles River Laboratories International's PEG ratio

Charles River Laboratories International's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.7185. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Charles River Laboratories International's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Charles River Laboratories International's EBITDA

Charles River Laboratories International's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $832.4 million.

The EBITDA is a measure of a Charles River Laboratories International's overall financial performance and is widely used to measure a its profitability.

Charles River Laboratories International financials

Revenue TTM $3.4 billion
Operating margin TTM 16.73%
Gross profit TTM $1.1 billion
Return on assets TTM 5.84%
Return on equity TTM 1834.6%
Profit margin 11.58%
Book value $48.09
Market capitalisation $17.9 billion

TTM: trailing 12 months

Charles River Laboratories International share dividends

We're not expecting Charles River Laboratories International to pay a dividend over the next 12 months.

Charles River Laboratories International share price volatility

Over the last 12 months, Charles River Laboratories International's shares have ranged in value from as little as $249.48 up to $460.21. A popular way to gauge a stock's volatility is its "beta".

CRL.US volatility(beta: 1.17)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Charles River Laboratories International's is 1.1713. This would suggest that Charles River Laboratories International's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Charles River Laboratories International overview

Charles River Laboratories International, Inc. , an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site